Currently, Immuneering Corp [IMRX] is trading at $6.56, down -4.51%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMRX shares have gain 4.13% over the last week, with a monthly amount glided 8.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immuneering Corp [NASDAQ: IMRX] stock has seen the most recent analyst activity on October 31, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $15. Previously, Morgan Stanley downgraded its rating to Underweight on December 13, 2024. On March 15, 2024, Needham reiterated its Buy rating and revised its price target to $15 on the stock. TD Cowen downgraded its rating to a Market Perform. Jefferies downgraded its rating to a Hold and reduced its price target to $3 on March 15, 2024. Needham started tracking with a Buy rating for this stock on December 01, 2023, and assigned it a price target of $20.
This stock has fluctuated between a low of $1.10 and a high of $10.08 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Immuneering Corp [NASDAQ: IMRX] shares were valued at $6.56 at the most recent close of the market. An investor can expect a potential return of 220.12% based on the average IMRX price forecast.
Analyzing the IMRX fundamentals
Gross Profit Margin for this corporation currently stands at -0.11% with Operating Profit Margin at -88.22%, Pretax Profit Margin comes in at -85.54%, and Net Profit Margin reading is -85.54%. To continue investigating profitability, this company’s Return on Assets is posted at -1.55, Equity is -1.46 and Total Capital is -1.97. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.33 points at the first support level, and at 6.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.97, and for the 2nd resistance point, it is at 7.38.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immuneering Corp [NASDAQ:IMRX] is 3.70. As well, the Quick Ratio is 3.70, while the Cash Ratio is 3.52.
Transactions by insiders
Recent insider trading involved Feinberg Peter, Director, that happened on Oct 03 ’25 when 7500.0 shares were purchased. Chief Accounting Officer, Morales Mallory completed a deal on Oct 01 ’25 to buy 300.0 shares. Meanwhile, CHIEF PEOPLE OFFICER Neufeld Leah R bought 800.0 shares on Oct 01 ’25.
